Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

Vertex Reveals Promising Data for Triple Combination Cystic Fibrosis Therapies

By Ryan Bushey | July 19, 2017

Vertex Pharmaceuticals is securing its spot leading the treatment space for cystic fibrosis (CF).

The company unveiled on Tuesday positive data from Phase I and Phase II studies for three different triple combination regimens for CF patients with certain types of gene mutations with one F508del mutation and one minimal function mutation (F508del/Min).

The drugs are labeled VX-659, VX-152, and VX-440, respectively.

VX-659 was tested in a randomized, double-blind, placebo-controlled study where investigators evaluated the safety and tolerability of single and multiple ascending doses of VX-659 alone as well as in triple combination with tezacaftor and ivacaftor in healthy volunteers. Also, the researchers explored the safety and tolerability of VX-659 as a component of a triple combination for two weeks in 12 patients with CF that were ages 18 and older with one F508del mutation and one minimal function mutation (3 in placebo and 9 in VX-659 120 mg), according to the announcement.

Results from this trial indicated the drug was generally well tolerated as part of the triple combination with tezacaftor and ivacaftor. Majority of adverse events were mild or moderate, but the data had shown there was an absolute improvement in ppFEV1 of 9.6 percentage points from the baseline in individuals receiving the triple combination of VX-659 (120mg q12h), tezacaftor, and ivacaftor.

VX-152 and VX-440 were tested in two small phase II studies. Patients who received 200 mg twice a day of VX-152 experienced a 9.7 percentage point improvement in ppFEV1 in volume of air exhaled in one second. Patients who were administered 600 mg of VX-440 twice a day as part of the triple combination experienced an improvement by 12 percentage points, reported Reuters.

“Patients with minimal function mutations have been waiting for a medicine to treat the underlying cause of their disease, which makes these data showing pronounced improvements in lung function particularly important,” said Steven M. Rowe, M.D., M.S.P.H, a professor of medicine leading steering committee comprised of CF experts for Vertex, in a statement. “It’s also encouraging to see that the addition of a next-generation corrector may lead to substantial additional benefits for patients with two copies of the F508del mutation, who were already receiving tezacaftor and ivacaftor.”

Vertex plans on gathering and evaluating more data from these studies and other experiments in order to advance further down the clinical development path by the first half of 2018.


Filed Under: Drug Discovery

 

Related Articles Read More >

If Trump gets Europe to pay more for drugs, more new medicines could follow — eventually
Antibody - visual concept of immune System - 3D illustration
Fresenius picks the biosimilars, WuXi Biologics builds them in a deal covering up to 37 candidates
Physician in a white coat reviewing information on a tablet with a patient in an exam room.
What real-world data shows about current cancer care
Roche Towers, Basel, Switzerland
Roche picks cancer targets, Hansoh builds the ADCs in deal with $400 million upfront
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE